Frovatriptan

Frovatriptan

File:Frovatriptan.svg
File:Frovatriptan Frova.gif
Clinical data
Pregnancy category	C: (USA) B3: (AUS)
Routes of administration	Oral
ATC code	N02CC07 (WHO)
Legal status
Legal status	Prescription only
Pharmacokinetic data
Bioavailability	20-30%
Metabolism	Hepatic
Elimination half-life	26 hours
Excretion	Renal
Identifiers
IUPAC name 6-methylamino-6,7,8,9-tetrahydro- 5H-carbazole-3-carboxamide
CAS Number	158930-17-7
PubChem CID	5284561
DrugBank	APRD00270
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C14H17N3O
Molar mass	243.304 g/mol

Frovatriptan (trade name Frova) is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.

Pharmacology

Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. It is available as 2.5 mg tablets.

Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans.

US licensing

Frovatriptan is available only by prescription in the United States, where a secondary New Drug Approval (sNDA) was filed in July 2006, and which is currently pending. The FDA anticipates completing its review of this application on or before the current PDUFA (Prescription Drug User Fee Act) review date of August 19, 2007. If the sNDA is approved, Frova will be the only medication indicated in the U.S. for the short-term prevention of menstrual migraine (MM).

External links

• Frova (manufacturer's website)
• Frovatriptan Succinate (patient information)

Template:Pharma-stub